Land: Israel
Sprog: engelsk
Kilde: Ministry of Health
CARIPRAZINE AS HYDROCHLORIDE
DEXCEL LTD, ISRAEL
N05AX15
HARD CAPSULE
CARIPRAZINE AS HYDROCHLORIDE 6 MG
PER OS
Required
GEDEON RICHTER PLC, HUNGARY
CARIPRAZINE
- For the treatment of schizophrenia in adult patients- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult- Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults
2020-01-27
Reagila ® 1.5, 3, 4.5, 6 Capsules PATIENT PACKAGE INSERT ACCORDING TO PHARMACISTS’ REGULATIONS )PREPARATIONS( - 1986 This medicine can be sold with a physician’s prescription only Each capsule contains cariprazine as hydrochloride salt at a dose of 1.5, 3, 4.5 or 6 mg respectively. Inactive ingredients and allergens in the medicine- see section 6 ”Additional information” and in section 2 ”Important information about some of the ingredients of this medicine”. READ THIS ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, ask the doctor or the pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if you think that their medical condition is similar to yours. 1. WHAT IS THE MEDICINE INTENDED FOR? Treatment of schizophrenia in adults. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Treatment of depressive episodes associated with bipolar I disorder in adults. REAGILA contains the active ingredient cariprazine and belongs to a group of medicines called antipsychotics. Schizophrenia is a disease characterized by symptoms such as hearing, seeing or sensing things which are not there )hallucinations(, suspiciousness, mistaken beliefs, incoherent speech and behavior and emotional flatness. People with this condition may also feel depressed, guilty, anxious, tense, or not being able to start or keep up planned activities, unwillingness to speak, lack of emotional response to a situation that would normally stimulate feelings in others. Bipolar disorder is a mental disorder that causes extreme mood changes. Extreme insane behavior is on one side of the disorder and severe depression is on the other. THERAPEUTIC GROUP: antipsychotic medicine. 2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE IF YOU: are hypersensitive )allergic( to the active ingredient )cariprazine( or to any of the other ingredients this medicine conta Læs hele dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Reagila 1.5 Reagila 3 Reagila 4.5 Reagila 6 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Reagila 1.5 Each hard capsule contains cariprazine hydrochloride corresponding to 1.5 mg cariprazine. Reagila 3 Each hard capsule contains cariprazine hydrochloride corresponding to 3 mg cariprazine. Excipient with known effect Each hard capsule contains 0.0003 mg Allura red AC (E 129). Reagila 4.5 Each hard capsule contains cariprazine hydrochloride corresponding to 4.5 mg cariprazine. Excipient with known effect Each hard capsule contains 0.0008 mg Allura red AC (E 129). Reagila 6 Each hard capsule contains cariprazine hydrochloride corresponding to 6 mg cariprazine. Excipient with known effect Each hard capsule contains 0.0096 mg Allura red AC (E 129). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule Reagila 1.5 White capsule imprinted with “GR 1.5” in black ink. Reagila 3 Green and white capsule imprinted with “GR 3” in black ink. Reagila 4.5 Green capsule imprinted with “GR 4.5” in white ink. Reagila 6 Purple and white capsule imprinted with “GR 6” in black ink. 2 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reagila is indicated for the: • Treatment of schizophrenia in adult patients. • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult. • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Schizophrenia _ The recommended starting dose of cariprazine is 1.5 mg once daily. Thereafter the dose can be increased slowly in 1.5 mg increments to a maximum dose of 6 mg/day, if needed. The lowest effective dose should be maintained according to the clinical judgement of the treating physician. Because of the long half-life of cariprazine and its active metabolites, changes in dose will not be fully reflected in plasma for several weeks. Patients should be monitored Læs hele dokumentet